

4-25-05

PCT

J007 Rec'd PCT/PTO 21 APR 2005

Please type a plus sign (+) inside this box →

[] +

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM


(to be used for all correspondence after initial filing)

		Application Number	10/519,128
		Filing Date	Not yet assigned
		First Named Inventor	LEE, RANDALL J.
		Group Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
Total Number of Pages in This Submission	8	Attorney Docket Number	UCAL-253US1

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> POSTCARD
<input checked="" type="checkbox"/> Information Disclosure Statement SB08A form	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Certified Copy of Priority Documents	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	<input type="checkbox"/> CD, Number of CD(s)	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		


SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Signing Attorney/Agent (Reg. No.)	CAROL L. FRANCIS, 36,513 BOZICEVIC, FIELD & FRANCIS, LLP
Signature	
Date	April 21, 2005

EXPRESS MAIL LABEL NO. EV577672655US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Express Mail No. EV577672655US

INFORMATION DISCLOSURE STATEMENT		
Address to:	Attorney Docket	UCAL-253US1
Mail Stop	First Named Inventor	LEE, RANDALL J.
Commissioner for Patents	Application Number	10/519,128
P.O. Box 1450	Confirmation No.	Not yet assigned
Alexandria, VA 22313-1450	Filing Date	Not yet assigned
	Group Art Unit	Not yet assigned
	Examiner Name	Not yet assigned
	Title:	"METHODS AND COMPOSITIONS FOR CORRECTION OF CARDIAC CONDUCTION DISTURBANCES"

Sir:


This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.


All of the references identified herein were disclosed in a related application serial number 10/291,202 filed 11/7/2002 and as such, copies thereof are not included pursuant to the provisions of 37 CFR § 1.98(d).

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. UCAL-253US1 may be charged thereon.

Date: April 21, 2005
BOZICEVIC, FIELD & FRANCIS LLP
1900 University Avenue, Suite 200
East Palo Alto, California 94303
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP
By: 
Carol L. Francis
Registration No. 36,513



Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
				Application Number	10/519,128
				Filing Date	Not yet assigned
				First Named Inventor	LEE, RANDALL J.
				Group Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
Sheet	1	of	6	Attorney Docket Number	UCAL-253US1

U.S. PATENT DOCUMENTS					
Examiner Initials'	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
		5,130,141		Law, et al.	07-14-1992
		6,059,726		Lee, et al.	05-09-2000
		6,151,525		Soykan, et al.	11-21-2000
		6,238,429		Markowitz, et al.	05-29-2001
		6,239,117		Christ, et al.	05-29-2001
		2001/0009986		Ponzi	07-26-2001
		2002/0013615		Haim, et al.	01-31-2002
		2002/0031501		Law	03-14-2002
		6,387,369		Pittenger, et al.	05-14-2002
		2002/0061295		Field	05-23-2002
		2002/0061587		Anversa	05-23-2002
		6,271,211		Christ et al.	08-07-2001
		6,415,178		Ben-Haim, et al.	07-02-2002
		US 2002/0001577		Haverich et al.	01-03-2002

FOREIGN PATENT DOCUMENTS					
Examiner Initials'	Cite No. ¹	Foreign Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY
		Office ³	Number ⁴	Kind Code ⁵ (if known)	
		WO	96/18303	Law	06-20-1996
		WO	98/02150	Stokes, et al.	01-22-1998
		WO	01/68814	Field	09-20-2001
		WO	03/094855	The Regents of the University of California & Rhythm Therapeutics Corp	11-20-2003
		WO	03/095016	The Regents of the University of California	11-20-2003
		WO	2004/050013	The Regents of the University of California	06-17-2004

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

O I P E

Please type a plus sign (+) inside this

APR 21 2005

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/519,128
				Filing Date	Not yet assigned
				First Named Inventor	LEE, RANDALL J.
				Group Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
Sheet	2	of	6	Attorney Docket Number	UCAL-253US1

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		American Heart Association. "2001 Heart and Stroke Statistical Update", Dallas, TX: American Heart Association, 1999.
		ATKINS, et al. "Cellular cardiomyoplasty improves diastolic properties of injured heart", <i>J. Surg. Res.</i> , (1999) Vol. 85: 234-242.
		ATKINS, et. al. "Myogenic cell transplantation improves <i>in vivo</i> regional performance in infarcted rabbit myocardium" <i>Cardiac and Vascular Regeneration</i> , (2000) Vol. 1: 43-53.
		ATKINS, et al. Cardiomyoplasty improves diastolic function in a rabbit model of myocardial injury", <i>Circulation</i> , (1998) Vol. 98: Supplement 1: 1227.
		ATKINS, et. al. "Intracardiac transplantation of skeletal myoblasts yields two populations of striated cells <i>in situ</i> ", <i>Ann Thorac Surg</i> , (1999) Vol. 67: 124-129.
		ATKINS, et al. "Differential effects of cellular cardiomyoplasty on systolic and diastolic performance in cryoinjured rabbit heart", <i>J Heart Lung Transpl.</i> , (1999) Vol. 18: 43.
		ATKINS, et al. "Transplanted autologous skeletal myoblasts improve myocardial performance after coronary artery ligation", <i>Cardiac and Vascular Regeneration</i> , (2000) Vol. 1: 76-84.
		BALOGH, et al. "Expression of gap junction in cultured rat L6 cells during myogenesis", <i>Developmental Biology</i> , (1993) Vol. 155: 351-360.
		BLAU. "Muscling in on gene therapy", <i>Nature</i> , (1993) Vol. 364: 673-675.
		BLAU, et al. "Myoblasts in pattern formation and gene therapy", <i>Trends in Genetics</i> , (1993) Vol. 9(8): 269-274.
		BRITTBURG, et al. "Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation", <i>The New England J of Med.</i> , (1994) Vol. 331: 889-895.
		Chachques, et al., "Cellular Therapy Reverses Myocardial Dysfunction" 1st Virtual Congress of Cardiology. The American Association of Thoracic Surgery (Abst) 2000:202
		CHIU. "Cardiac cell transplantation: The autologous skeletal myoblast implantation for myocardial regeneration", <i>Adv Card Surg</i> , (1999) Vol. 11: 69-98.
		CHIU, et al. "Cellular cardiomyoplasty: Myocardial regeneration with satellite cell implantation", <i>Ann Thorac Surg</i> , (1995) Vol. 60: 12-18.
		DAHL, et al. "Expression of gap junction genes, connexin40 and connexin43, during fetal mouse development", <i>Anat. Embryol.</i> , (1995) Vol. 191: 267-278.
		DAI, et al. "Gene therapy via primary myoblasts: Long-term expression of factor IX protein following transplantation <i>in vivo</i> ", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 89: 10892-10895.

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

APR 21 2005

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p style="text-align: center;"><i>(use as many sheets as necessary)</i></p>				Complete if Known							
				<table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td>Application Number</td><td>10/519,128</td></tr> <tr><td>Filing Date</td><td>Not yet assigned</td></tr> <tr><td>First Named Inventor</td><td>LEE, RANDALL J.</td></tr> <tr><td>Group Art Unit</td><td>Not yet assigned</td></tr> <tr><td>Examiner Name</td><td>Not yet assigned</td></tr> </table>		Application Number	10/519,128	Filing Date	Not yet assigned	First Named Inventor	LEE, RANDALL J.
Application Number	10/519,128										
Filing Date	Not yet assigned										
First Named Inventor	LEE, RANDALL J.										
Group Art Unit	Not yet assigned										
Examiner Name	Not yet assigned										
Sheet	3	of	6	Attorney Docket Number	UCAL-253US1						


	Davis, et al., "Modulation of connexin43 expression: effects on cellular coupling", <i>Journal of Cardiovascular Electrophysiology</i> , 1995, vol. 6, no. 2, pgs 103-114
	DHAWAN, et al. "Systemic delivery of human growth hormone by injection of genetically engineered myoblasts", <i>Science</i> , (1991) Vol. 254: 1509-1512;
	DOROZYNSKI. "Transplanted cells revive heart muscle", <i>British Medical Journal</i> , (2000) Vol. 321(Issue 7268): 1040-1041.
	EL OAKLEY, et al. "Myocyte transplantation for myocardial repair: A few good cells can mend a broken heart", <i>Ann Thorac Surg</i> . (2001) Vol. 71(5): 1724-1733.
	First ever transplantation of skeletal muscle cells to test whether the cells can repair damaged heart muscle. PR Newswire 9/25/00. http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-25-2000/0001321663&EDATE=
	Field, et al., "Electrophysiological Modulation of Cardiomyocytic Tissue by Transfected Fibroblasts Expressing Potassium Channels" <i>Circulation</i> . 105:522-529 (2002)
	GAGE, et al. "Genetically modified cells: Applications for intracerebral grafting", <i>Trends in Neuroscience</i> , (1991) Vol. 14(8): 328-333.
	GenBank Accession No. AA511201
	GenBank Accession No. AA530689
	GenBank Accession No. AA822279
	GenBank Accession No. AA855990
	GenBank Accession No. AF151980
	GenBank Accession No. AH003191
	GenBank Accession No. M61896
	GenBank Accession No. M65188
	GenBank Accession No. N86403
	GenBank Accession No. NM 000165
	GenBank Accession No. NM 010288
	GenBank Accession No. NM 012567
	GenBank Accession No. X61576
	GenBank Accession No. X62836
	GUSSONI, et al. "Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation", <i>Nature</i> , (1992) Vol. 356: 435-438.
	HUSTEN. "Global epidemic of cardiovascular disease predicted", <i>Lancet</i> , (1998) Vol. 352: 1530.
	JANUS, et al. "The modernization of Asia: Implications for coronary heart disease", <i>Circulation</i> , (1996) Vol. 94: 2671-2673.
	KAO, et al. "Satellite cell transplantation to repair injured myocardium", <i>Cardiac and Vascular Regeneration</i> , (2000) Vol. 1: 31-42.

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete If Known	
Sheet	4	of	6	Attorney Docket Number	UCAL-253US1

	KESSLER, et al. "Myoblast cell grafting into heart muscle: Cellular biology and potential applications", <i>Annu Rev Physiol.</i> , (1999) Vol. 61: 219-242.
	KNUDSEN, et al. "A role for the Ca ²⁺ -dependent adhesion molecule, N-cadherin, in myoblast interaction during myogenesis", <i>Exp. Cell Res.</i> , (1990) Vol. 188: 175-184.
	KOUTOUZIS, et al. "Cell transplantation for central nervous system disorders", <i>Critical Reviews in Neurobiol.</i> , (1994) Vol. 8(3): 125-162.
	KHURANA et al. Gene Therapy For Cardiovascular Disease. A Case for Cautious Optimis. Hypertension 2001, Vol. 38, pages 1210-1216
	LAW, et al. "Cell transplantation as an experimental treatment for Duchenne muscular dystrophy", <i>Transplantation</i> , (1993) Vol. 2: 485-505.
	LEE, et al. "Coupling requirements for successful impulse propagation with skeletal myocytes transplanted in myocardium", <i>Annals of Biomedical Engineering</i> , (2000) Vol. 28(Supp 1): S54: T6.10.
	Long, et al., "The Cardiac Fibroblast, Another Therapeutic target for Mending the Broken Heart" <i>J. Mol Cell Cardiol.</i> 34; 1273-1278 (2002).
	MACCALMAN, et al. "Noncoordinate developmental regulation of N-cadherin, N-CAM, integrin, and fibronectin mRNA levels during myoblast terminal differentiation", <i>Developmental Dynamics</i> , (1992) Vol. 195: 127-132.
	MARELLI, et al. "Satellite cell implantation for neomyocardial regeneration", <i>Transplantation Proceedings</i> , (1992) Vol. 24(6): 2995.
	MENASCHÉ, et al. "Myoblast transplantation for heart failure", <i>Lancet</i> , (2001) Vol. 357: 279-280.
	MURRAY, et al. "Skeletal myoblast transplantation for repair of myocardial necrosis", <i>J Clin Invest.</i> , (1996) Vol. 98(11): 2512-2523.
	Murry, et al., "Muscle Cell Grafting for the Treatment and Prevention of Heart Failure" <i>J. of Cardiac Failure</i> Vol. 8 n°6 Suppl (2002)
	MYERBURG, et al. "Sudden cardiac death: Structure, function, and time-dependence of risk", <i>Circulation</i> , (1992) Vol. 85(1): I2-I10.
	NICHOLAS et al., "Immunocytochemical Analysis of Connexin Expression in the Healthy and Diseased Cardiovascular System", <i>Microscopy Res. Technique</i> . 2001, Vol. 52, pages 301-322
	ORLIC, et al. "Bone marrow cells regenerate infarcted myocardium", <i>Nature</i> , (2001) Vol. 410: 701-705.
	PESCHANSKI, et al. "Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon", <i>Brain</i> , (1994) Vol. 117: 487-499.
	PFEFFER, et al. "Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction", <i>New England J. of Med.</i> , (1988) Vol. 319: 80-86.

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/519,128	
Sheet	5	of	6	Filing Date	Not yet assigned	
				First Named Inventor	LEE, RANDALL J.	
				Group Art Unit	Not yet assigned	
				Examiner Name	Not yet assigned	
				Attorney Docket Number		UCAL-253US1


		RAJNOCH, et al. "Cellular therapy reverses myocardial dysfunction", <i>J. Thoracic Cardiovascular Surgery</i> , (2001) Vol. 121(5): 871-878.	
		REINECKE, et al. "Electromechanical coupling between skeletal and cardiac muscle: Implications for infarct repair", <i>J. Cell Biol.</i> , (2000) Vol. 149(3): 731-740.	
		REINECKE, et al. "Transmural replacement of myocardium after skeletal myoblast grafting into the heart: Too much of a good thing?" <i>Cardiovasc Pathol.</i> , (2000) Vol. 9(6): 337-344.	
		ROBINSON, et al. "Arterial delivery of genetically labeled skeletal myoblasts to the murine heart: Long-term survival and phenotypic modification of implanted myoblasts", <i>Cell Transplantation</i> , (1996) Vol. 5(1): 77-91.	
		Suzuki et al, "Overexpression of connexin 43 in skeletal myoblasts: relevance to cell transplantation to the heart", <i>The Journal of Thoracic and Cardiovascular Surgery</i> ", 2001, vol. 122, no. 4, pgs. 759-766	
		SCORSIN, et al. "Comparison of the effects of fetal cardiomyocyte and skeletal myoblast transplantation on postinfarction left ventricular function", <i>J Thoracic Cardiovascular Surgery</i> , (2000) Vol. 119: 1169-1175.	
		SOONPA, et al. "Formation of nascent intercalated disks between grafted fetal cardiomyocytes and host myocardium", <i>Science</i> , (1994) Vol. 264: 98-101.	
		SPRINGER, et al. "VEGF gene delivery to muscle: Potential role for vasculogenesis in adults", <i>Molecular Cell</i> , (1998) Vol. 2: 549-558.	
		SPRINGER, et al. "High-efficiency retroviral infection of primary myoblasts", <i>Cell Mol. Genet.</i> , (1997) Vol. 23 (3): 203-209.	
		SUZUKI, et al. "Overexpression of connexin 43 in skeletal myoblasts: Relevance to cell transplantation to the heart", <i>J. Thoracic and Cardiovascular Surgery</i> , (2001) Vol. 122(4): 759-766.	
		TAM, et al. "Molecular cardiomyoplasty: Potential cardiac gene therapy for chronic heart failure", <i>J. of Thoracic and Cardiovascular Surgery</i> , (1995): Vol. 109(5): 918-924.	
		TAYLOR, et al. "Regenerating functional myocardium: Improved performance after skeletal myoblast transplantation", <i>Nature Medicine</i> , (1998) Vol. 4(8): 929-933.	
		TAYLOR, et al. "Delivery of primary autologous skeletal myoblasts into rabbit heart by coronary infusion: A potential approach to myocardial repair", <i>Proceedings of the Association of American Physicians</i> , (1997) Vol. 109:245-253.	
		TREMBLAY, et al. "Results of a triple blind clinical study of myoblast transplants without immunosuppressive treatment in young boys with Duchenne muscular dystrophy", <i>Cell Transplantation</i> , (1993) Vol. 2: 99-112.	
		VERHEULE, et al. "Characterization of gap junction channels in adult rabbit atrial and ventricular myocardium", <i>Cir. Res.</i> , (1997) Vol. 80: 673-681.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	6	of	6	Application Number	10/519,128
				Filing Date	Not yet assigned
				First Named Inventor	LEE, RANDALL J.
				Group Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
				Attorney Docket Number	UCAL-253US1

	WEISEL, et al. "Cell transplantation comes of age", <i>J Thoracic Cardiovascular Surgery</i> , (2001) Vol. 121(5): 835-836.	
	YANG et al. VEGF Enhances Functional Improvement of Postinfarcted Hearts By Transplantation of ESC-Differentiated Cells. <i>J. Appl. Physiol.</i> 2002, Vol. 93, pages 1140-1151	
	ZWIEBEL, et al. "Drug delivery by genetically engineered cell implants", <i>Annals of the New York Academy of Sciences</i> , (1991) Vol. 618: 394-404.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.